Announcements Trials
Browse Landscape

Phase

Phase NA 3

Status

Unknown 3

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 26Small Cell Lung Carcinoma 10Sarcoma 8Breast Neoplasms 8Carcinoma, Hepatocellular 7Lung Neoplasms 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma 4Non-squamous Non-small Cell Lung Cancer 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Thyroid Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neoplasms 2Liver Neoplasms 2Gynecological Cancer 2Extensive Stage Small Cell Lung Cancer 2Esophageal Neoplasms 2Endometrial Neoplasms 2Digestive System Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumor 2Squamous Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Pemetrexed 4anlotinib 3Platinum 2Bevacizumab 2icotinib 1endostar protein 1Gefitinib 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Non-squamous Non-small Cell Lung Cancer × anlotinib × Clear all
NCT03671538 2018-09-17

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

The First Affiliated Hospital of Nanchang University

Phase NA Unknown
62 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

NCT03602027 2018-07-26

Phase I Study of the Combination of Anlotinib With Gefitinib

Second Affiliated Hospital of Nanchang University

Phase NA Unknown
9 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

NCT03566576 2018-06-25

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Fujian Cancer Hospital

Phase NA Unknown
18 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡